For research use only. Not for therapeutic Use.
Eravacycline dihydrochloride(Cat No.:I013150) is a potent and broad-spectrum antibacterial agent. It belongs to the class of tetracycline antibiotics and is specifically designed to overcome resistance mechanisms that can limit the efficacy of other antibiotics. Eravacycline works by inhibiting bacterial protein synthesis, thereby preventing the growth and proliferation of bacteria. It has demonstrated activity against a wide range of Gram-positive and Gram-negative pathogens, including multidrug-resistant strains. Eravacycline dihydrochloride has been investigated for its potential in treating various infections, including complicated intra-abdominal infections and complicated urinary tract infections.
| Catalog Number | I013150 |
| CAS Number | 1334714-66-7 |
| Molecular Formula | C₂₇H₃₃Cl₂FN₄O₈ |
| Purity | ≥95% |
| Target | Beta-lactamase |
| Solubility | H2O |
| IUPAC Name | (4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;dihydrochloride |
| InChI | InChI=1S/C27H31FN4O8.2ClH/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39;;/h9,11,13,20,34-35,38,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33);2*1H/t11-,13-,20-,27-;;/m0../s1 |
| InChIKey | XIBSSTYDNTVAEU-RZVFYPHASA-N |
| SMILES | CN(C)C1C2CC3CC4=C(C=C(C(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F.Cl.Cl |
| Reference | [1]. Seifert H, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017 Jul 10.<br>[2]. Zhao M, et al. In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrob Agents Chemother. 2017 Jun 27;61(7).<br>[3]. Xiao XY, et al. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem. 2012 Jan 26;55(2):597-605. <br>[4]. Sutcliffe JA, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. <br>[5]. Grossman TH, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015 May;59(5):2567-71. |
